Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending August 19, 2018
Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894
For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035
Concerns rise over proposal by CMS to level E/M payments , CMS proposed rule, CMS-1693-P
Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA
Promise of broad genomic testing of NSCLC disappoints in community oncology , Presley CJ et al. JAMA. 2018 Aug 7. doi: 10.1001/jama.2018.9824
Must reads for theWeek ending August 12, 2018
Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7
CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P
Two novel TKIs better than one in GIST with multiple KIT mutations, Wagner AJ et al. ASCO 2018, Abstract 11509.
PFS better with trofosfamide than doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomas, Hartman JT et al. ASCO 2018, Abstract 11507.
Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.
Must reads for theWeek ending August 5, 2018
Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.
Avatrombopag reduces procedure-related transfusions in chronic liver disease and thrombocytopenia, Terrault N et al. Gastroenterology. 2018 May 17. doi: 10.1053/j.gastro.2018.05.025.
Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.
Study evaluates surveillance intervals after Barrett's esophagus ablation, Cotton CC et al. Gastroenterology. 2018 Apr 12. doi: 10.1053/j.gastro.2018.04.011.
Pregnancy does not increase melanoma recurrence risk, DiSano JA et al. J Surg Res. 2018 Jun 16. doi: 10.1016/j.jss.2018.05.026.
Must reads for theWeek ending July 22, 2018
Combo therapy after disease progression no advantage in chemotherapy-naïve metastatic castration-resistant prostate cancer, Attard G et al. Journal of Clinical Oncology; published online 20 July 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.77.9827
Poorer RCC outcomes with incidental upstaging after partial nephrectomy, Russell C et al. Urology; July 2018, 95-100. https://doi.org/10.1016/j.urology.2018.04.002
Good results seen with laparoscopic partial nephrectomy following selective embolization of tumor, Benoit M et al. Clinical Genitourinary Cancer: Published online 12 July 2018 https://doi.org/10.1016/j.clgc.2018.07.005.
In metastatic hormone-sensitive prostate cancer, prior local therapy is linked to improved survival, Abdel-Rahman O and Cheung W. Clinical Genitourinary Cancer; published online 21 July 2018 https://doi.org/10.1016/j.clgc.2018.07.007
In sarcomatoid renal-cell carcinomas, 3-drug combo falls short, Maiti A et al. Clinical Genitourinary Cancer 2018 e47-e57 https://doi.org/10.1016/j.clgc.2017.07.028
Must reads for theWeek ending July 22, 2018
Combo therapy after disease progression no advantage in chemotherapy-naïve metastatic castration-resistant prostate cancer, Attard G et al. Journal of Clinical Oncology; published online 20 July 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.77.9827
Poorer RCC outcomes with incidental upstaging after partial nephrectomy, Russell C et al. Urology; July 2018, 95-100. https://doi.org/10.1016/j.urology.2018.04.002
Good results seen with laparoscopic partial nephrectomy following selective embolization of tumor, Benoit M et al. Clinical Genitourinary Cancer: Published online 12 July 2018 https://doi.org/10.1016/j.clgc.2018.07.005.
In metastatic hormone-sensitive prostate cancer, prior local therapy is linked to improved survival, Abdel-Rahman O and Cheung W. Clinical Genitourinary Cancer; published online 21 July 2018 https://doi.org/10.1016/j.clgc.2018.07.007
In sarcomatoid renal-cell carcinomas, 3-drug combo falls short, Maiti A et al. Clinical Genitourinary Cancer 2018 e47-e57 https://doi.org/10.1016/j.clgc.2017.07.028